Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy.
Greene E, Finak G, D'Amico LA, Bhardwaj N, Church CD, Morishima C, Ramchurren N, Taube JM, Nghiem PT, Cheever MA, Fling SP, Gottardo R. Greene E, et al. Among authors: ramchurren n. Patterns (N Y). 2021 Oct 27;2(12):100372. doi: 10.1016/j.patter.2021.100372. eCollection 2021 Dec 10. Patterns (N Y). 2021. PMID: 34950900 Free PMC article.
IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser JC, Morre M, Grégoire A, Cheever M, Yu EY, Fong L. Pachynski RK, et al. Among authors: ramchurren n. J Immunother Cancer. 2021 Aug;9(8):e002903. doi: 10.1136/jitc-2021-002903. J Immunother Cancer. 2021. PMID: 34452927 Free PMC article. Clinical Trial.
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.
Bhardwaj N, Friedlander PA, Pavlick AC, Ernstoff MS, Gastman BR, Hanks BA, Curti BD, Albertini MR, Luke JJ, Blazquez AB, Balan S, Bedognetti D, Beechem JM, Crocker AS, D'Amico L, Danaher P, Davis TA, Hawthorne T, Hess BW, Keler T, Lundgren L, Morishima C, Ramchurren N, Rinchai D, Salazar AM, Salim BA, Sharon E, Vitale LA, Wang E, Warren S, Yellin MJ, Disis ML, Cheever MA, Fling SP. Bhardwaj N, et al. Among authors: ramchurren n. Nat Cancer. 2020 Dec;1(12):1204-1217. doi: 10.1038/s43018-020-00143-y. Epub 2020 Nov 16. Nat Cancer. 2020. PMID: 35121932 Clinical Trial.
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses.
Odunsi K, Qian F, Lugade AA, Yu H, Geller MA, Fling SP, Kaiser JC, Lacroix AM, D'Amico L, Ramchurren N, Morishima C, Disis ML, Dennis L, Danaher P, Warren S, Nguyen VA, Ravi S, Tsuji T, Rosario S, Zha W, Hutson A, Liu S, Lele S, Zsiros E, McGray AJR, Chiello J, Koya R, Chodon T, Morrison CD, Putluri V, Putluri N, Mager DE, Gunawan R, Cheever MA, Battaglia S, Matsuzaki J. Odunsi K, et al. Among authors: ramchurren n. Sci Transl Med. 2022 Mar 16;14(636):eabg8402. doi: 10.1126/scitranslmed.abg8402. Epub 2022 Mar 16. Sci Transl Med. 2022. PMID: 35294258 Free PMC article.
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Nghiem P, et al. Among authors: ramchurren n. J Immunother Cancer. 2021 Apr;9(4):e002478. doi: 10.1136/jitc-2021-002478. J Immunother Cancer. 2021. PMID: 33879601 Free PMC article. Clinical Trial.
PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.
Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N. Simon S, et al. Among authors: ramchurren n. J Immunother Cancer. 2020 Nov;8(2):e001631. doi: 10.1136/jitc-2020-001631. J Immunother Cancer. 2020. PMID: 33188038 Free PMC article.
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH. Khodadoust MS, et al. Among authors: ramchurren n. J Clin Oncol. 2020 Jan 1;38(1):20-28. doi: 10.1200/JCO.19.01056. Epub 2019 Sep 18. J Clin Oncol. 2020. PMID: 31532724 Free PMC article. Clinical Trial.
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Beygi S, Fernandez-Pol S, Duran G, Wang EB, Stehr H, Zehnder JL, Ramchurren N, Fling SP, Cheever MA, Weng WK, Kim YH, Khodadoust MS. Beygi S, et al. Among authors: ramchurren n. Blood Adv. 2021 Feb 9;5(3):771-774. doi: 10.1182/bloodadvances.2020002371. Blood Adv. 2021. PMID: 33560388 Free PMC article.
36 results